Research graph
References from Preliminary Evaluation of 225Ac/177Lu-DOTATATE PRRT in Progressive Meningiomas. Local targets link to admitted publications; unresolved targets remain external evidence.
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
10.1093/neuonc/noab106 · 2021 · External reference
The outcome of patients with surgically treated meningioma in England: 1999–2013. a cancer registry data analysis
10.1080/02688697.2019.1661965 · 2019 · External reference
Stereotactic radiosurgery for WHO II and III meningiomas: analysis of long-term clinical and radiographic outcomes
2013 · External reference
EANO guideline on the diagnosis and management of meningiomas
10.1093/neuonc/noab150 · 2021 · External reference
Chemotherapy and targeted therapies for meningiomas: what is the evidence?
10.1097/wco.0000000000001002 · 2021 · External reference
An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy
10.1007/s00259-019-04578-z · 2020 · External reference
Feasibility and therapeutic potential of peptide receptor radionuclide therapy for high-grade gliomas
10.1097/rlu.0000000000003599 · 2021 · External reference
An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care
10.21037/qims.2019.08.16 · 2019 · External reference
Theranostics in brain tumors
10.1016/j.cpet.2021.03.005 · 2021 · External reference
Somatostatin-receptor-targeted radionuclide therapy for progressive me ningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake
2016 · External reference
Theragnostic for meningiomas: new benefits in molecular imaging.39. 225Ac-DOTATATE dosimetry results from part 1 of the ACTION-1 Trial
2023 · External reference
Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide the rapy targets in higher-grade meningioma
10.1007/s00259-025-07075-8 · 2025 · External reference
Somatostatin receptor theranostics for refractory meningiomas
10.3390/curroncol29080438 · 2022 · External reference
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTAT ATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTAT ATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors
10.4103/wjnm.wjnm_39_18 · 2019 · External reference
Retrospective evaluation of the correlation between somatostatin receptor PET/CT and histopathology in patients with suspected intracranial meningiomas
10.2967/jnumed.125.270115 · 2025 · External reference
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
10.1093/neuonc/not330 · 2014 · External reference
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
10.1093/neuonc/noy137 · 2019 · External reference
3D Slicer as an image computing platform for the Quantitative Imaging Network
10.1016/j.mri.2012.05.001 · 2012 · External reference
LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity
10.1158/0008-5472.can-18-0125 · 2018 · External reference
Radioligand therapies in meningioma: evidence and future directions
10.1093/neuonc/noae069 · 2024 · External reference
The current role of peptide receptor radionuclide therapy in meningiomas
10.3390/jcm11092364 · 2022 · External reference
Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: a RANO group systematic review and meta-analysis to guide clinical trial design
10.1093/neuonc/noaf009 · 2025 · External reference
Peptide receptor radionuclide therapy in advanced refractory meningiom as: efficacy and toxicity in a long follow-up
10.2967/jnumed.123.266956 · 2024 · External reference
Advances With (225)Ac-DOTATATE targeted alpha therapy in somatostatin receptor positive neuroendocrine tumors
10.1053/j.semnuclmed.2025.06.008 · 2025 · External reference
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma
10.1158/1078-0432.ccr-23-2533 · 2023 · External reference
Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma
10.1016/j.omton.2024.200782 · 2024 · External reference
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
10.1093/neuonc/noae082 · 2024 · External reference
An update on DOTA-peptides PET imaging and potential advancements of r adioligand therapy in intracranial meningiomas
10.3390/life15040617 · 2025 · External reference
177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review
10.23736/s1824-4785.24.03571-4 · 2024 · External reference
Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy
10.1007/s00330-023-09697-8 · 2023 · External reference
Somatostatin receptor–targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long -term results of a phase II clinical trial
10.2967/jnumed.114.147256 · 2015 · External reference
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0
10.1007/s00259-024-06783-x · 2024 · External reference
Clinical value of semi-quantitative parameters in 68Ga-DOTANOC PET/CT in treatment and diagnostics of cranial meningioma in a single-center retrospective analysis
10.1186/s41824-024-00204-w · 2024 · External reference
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma
10.1007/s00259-009-1115-z · 2009 · External reference
Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow
10.1088/1361-6560/abd3ef · 2021 · External reference
225Ac-DOTATATE dosimetry results from part 1 of the ACTION-1 Trial
2023 · External reference
The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges
10.1038/s41388-020-01568-6 · 2021 · External reference
Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes
10.1007/s00401-023-02635-4 · 2023 · External reference
Evolving concepts in meningioma management in the era of genomics
10.1002/cncr.35279 · 2024 · External reference
Evolving concepts in meningioma management in the era of genomics
10.1002/cncr.35279 · ExternalCitation · doi-reference
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma
10.1007/s00259-009-1115-z · ExternalCitation · doi-reference
An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy
10.1007/s00259-019-04578-z · ExternalCitation · doi-reference
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0
10.1007/s00259-024-06783-x · ExternalCitation · doi-reference
Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide the rapy targets in higher-grade meningioma
10.1007/s00259-025-07075-8 · ExternalCitation · doi-reference
Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy
10.1007/s00330-023-09697-8 · ExternalCitation · doi-reference
Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes
10.1007/s00401-023-02635-4 · ExternalCitation · doi-reference
Theranostics in brain tumors
10.1016/j.cpet.2021.03.005 · ExternalCitation · doi-reference
3D Slicer as an image computing platform for the Quantitative Imaging Network
10.1016/j.mri.2012.05.001 · ExternalCitation · doi-reference
Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma
10.1016/j.omton.2024.200782 · ExternalCitation · doi-reference
The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges
10.1038/s41388-020-01568-6 · ExternalCitation · doi-reference
Advances With (225)Ac-DOTATATE targeted alpha therapy in somatostatin receptor positive neuroendocrine tumors
10.1053/j.semnuclmed.2025.06.008 · ExternalCitation · doi-reference
The outcome of patients with surgically treated meningioma in England: 1999–2013. a cancer registry data analysis
10.1080/02688697.2019.1661965 · ExternalCitation · doi-reference
Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow
10.1088/1361-6560/abd3ef · ExternalCitation · doi-reference
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
10.1093/neuonc/noab106 · ExternalCitation · doi-reference
EANO guideline on the diagnosis and management of meningiomas
10.1093/neuonc/noab150 · ExternalCitation · doi-reference
Radioligand therapies in meningioma: evidence and future directions
10.1093/neuonc/noae069 · ExternalCitation · doi-reference
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
10.1093/neuonc/noae082 · ExternalCitation · doi-reference
Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: a RANO group systematic review and meta-analysis to guide clinical trial design
10.1093/neuonc/noaf009 · ExternalCitation · doi-reference
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
10.1093/neuonc/not330 · ExternalCitation · doi-reference
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
10.1093/neuonc/noy137 · ExternalCitation · doi-reference
Feasibility and therapeutic potential of peptide receptor radionuclide therapy for high-grade gliomas
10.1097/rlu.0000000000003599 · ExternalCitation · doi-reference
Chemotherapy and targeted therapies for meningiomas: what is the evidence?
10.1097/wco.0000000000001002 · ExternalCitation · doi-reference
LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity
10.1158/0008-5472.can-18-0125 · ExternalCitation · doi-reference
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma
10.1158/1078-0432.ccr-23-2533 · ExternalCitation · doi-reference
Clinical value of semi-quantitative parameters in 68Ga-DOTANOC PET/CT in treatment and diagnostics of cranial meningioma in a single-center retrospective analysis
10.1186/s41824-024-00204-w · ExternalCitation · doi-reference
An update on PET-based molecular imaging in neuro-oncology: challenges and implementation for a precision medicine approach in cancer care
10.21037/qims.2019.08.16 · ExternalCitation · doi-reference
177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review
10.23736/s1824-4785.24.03571-4 · ExternalCitation · doi-reference
Somatostatin receptor–targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long -term results of a phase II clinical trial
10.2967/jnumed.114.147256 · ExternalCitation · doi-reference
Peptide receptor radionuclide therapy in advanced refractory meningiom as: efficacy and toxicity in a long follow-up
10.2967/jnumed.123.266956 · ExternalCitation · doi-reference
Retrospective evaluation of the correlation between somatostatin receptor PET/CT and histopathology in patients with suspected intracranial meningiomas
10.2967/jnumed.125.270115 · ExternalCitation · doi-reference
Somatostatin receptor theranostics for refractory meningiomas
10.3390/curroncol29080438 · ExternalCitation · doi-reference
The current role of peptide receptor radionuclide therapy in meningiomas
10.3390/jcm11092364 · ExternalCitation · doi-reference
An update on DOTA-peptides PET imaging and potential advancements of r adioligand therapy in intracranial meningiomas
10.3390/life15040617 · ExternalCitation · doi-reference
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTAT ATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTAT ATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors
10.4103/wjnm.wjnm_39_18 · ExternalCitation · doi-reference
